Fluticasone propionate

Fluticasone propionate

Clinical data
Trade names	Flixotide (inhalatory), Flixonase and Flonase (nasal)
AHFS/Drugs.com	Monograph
Pregnancy category	US: C (Risk not ruled out) C for Intranasal and Inhaled
Routes of administration	Intranasal, Inhaled, Topical Cream or Ointment
ATC code	D07AC17 (WHO) & D07AC04 (WHO) (topical)
Legal status
Legal status	UK: P (Pharmacy medicines) US: OTC
Pharmacokinetic data
Bioavailability	0.51% (Intranasal)
Protein binding	91%
Metabolism	Intranasal Hepatic (CYP3A4-mediated)
Biological half-life	10 hours
Excretion	Renal
Identifiers
IUPAC name S-(fluoromethyl)-6α,9-difluoro-11β, 17-dihydroxy-16α-methyl-3-oxoandrosta-1, 4-diene-17β-carbothioate, 17-propanoate
CAS Number	80474-14-2 Y
PubChem CID	444036
IUPHAR/BPS	7080
DrugBank	DB00588 Y
ChemSpider	392059 Y
UNII	O2GMZ0LF5W
ChEBI	CHEBI:31441 Y
ChEMBL	CHEMBL1473 Y
ECHA InfoCard	100.129.097
Chemical and physical data
Formula	C25H31F3O5S
Molar mass	500.57 g/mol
3D model (Jmol)	Interactive image
SMILES O=C(SCF)[C@]3(OC(=O)CC)[C@]2(C[C@H](O)[C@]4(F)[C@@]/1(\C(=C/C(=O)\C=C\1)[C@@H](F)C[C@H]4[C@@H]2C[C@H]3C)C)C
InChI InChI=1S/C25H31F3O5S/c1-5-20(31)33-25(21(32)34-12-26)13(2)8-15-16-10-18(27)17-9-14(29)6-7-22(17,3)24(16,28)19(30)11-23(15,25)4/h6-7,9,13,15-16,18-19,30H,5,8,10-12H2,1-4H3/t13-,15+,16+,18+,19+,22+,23+,24+,25+/m1/s1 Y Key:WMWTYOKRWGGJOA-CENSZEJFSA-N Y

Fluticasone propionate belongs to a class of drugs known as corticosteroids, specifically glucocorticoids, which are hormones that predominantly affect the metabolism of carbohydrates and, to a lesser extent, fat and protein. It is used to treat asthma, allergic rhinitis, nasal polyps, various skin disorders and Crohn's disease and ulcerative colitis. It is also used to treat eosinophilic esophagitis.

Fluticasone is used by powder or aerosol inhalation for the prophylaxis of asthma. Typical initial doses in the UK range from 100 to 250 micrograms twice daily in mild asthma up to 1 mg twice daily in severe asthma, adjusted according to response. Children over four years of age may be given initial doses of 50 to 100 micrograms twice daily, increased to 200 micrograms twice daily if necessary. The drug may also be given via a nebuliser in severe chronic asthma. Usual adult doses are 0.5 to 2 mg twice daily. Children aged four to sixteen years may be given 1 mg twice daily.

Nasal spray preparation of fluticasone propionate is used in the prophylaxis and treatment of allergic rhinitis. The usual dose is 100 micrograms into each nostril once daily, increased if necessary to 100 micrograms into each nostril twice daily. Children aged 4-11 years may be given half these doses.

Fluticasone propionate nasal drops are used in the treatment of nasal polyps.

Creams and ointments containing 0.05% and 0.005% Fluticasone propionate, respectively, are available and applied topically in the treatment of various skin disorders. It can be given orally in the treatment of Crohn’s disease and ulcerative colitis. Some benefit was also reported in coeliac disease. The dose is 5 mg four times daily but some consider higher doses necessary.